Cell Growth & Differentiation, Vol 5, Issue 7 753-759, Copyright © 1994 by American Association of Cancer Research

ARTICLES

Retroviral vector-mediated overexpression of the RII beta subunit of the cAMP-dependent protein kinase induces differentiation in human leukemia cells and reverts the transformed phenotype of mouse fibroblasts

G Tortora, A Budillon, H Yokozaki, T Clair, S Pepe, G Merlo, C Rohlff and YS Cho-Chung
Cellular Biochemistry Section, National Cancer Institute, NIH, Bethesda, Maryland 20892.

We have recently shown, using antisense strategy, that the RII beta regulatory subunit of cAMP-dependent protein kinase is essential for cAMP-induced growth inhibition and differentiation of HL-60 human leukemia cells. We constructed a retroviral vector for RII beta (MT-RII beta) by inserting human RII beta complementary DNA into the OT1521 retroviral vector plasmid that contains an internal mouse metallothionein-1 promoter and a neomycin resistance gene. The PA317 packaging cell line was then transfected with MT-RII beta plasmid to produce the amphotrophic stock of MT-RII beta retroviral vector. The infection with MT-RII beta and treatment with CdCl2 brought about growth arrest in HL-60 human leukemia and Ki-ras-transformed NIH 3T3 clone DT cells in monolayer culture with no sign of toxicity. The growth inhibition correlated with the expression of RII beta and accompanied changes in cell morphology; cells became flat, exhibiting enlarged cytoplasm. The growth of these cells in semisolid medium (anchorage-independent growth) was almost completely suppressed. In contrast, overexpression of the RI alpha subunit of protein kinase enhanced the cell proliferation in DT cells. The MT-RII beta-infected cells exhibited an increased sensitivity toward treatment with cAMP analogues, such as 8-Cl-cAMP and N6-benzyl-cAMP, as compared with the parental noninfected cells. In MT-RII beta HL-60 cells, N6-benzyl-cAMP treatment greatly enhanced the expression of monocytic surface markers. These results suggest that the RII beta cAMP receptor, by binding to its ligand, cAMP, acts as a tumor suppressor protein exerting growth inhibition, differentiation, and reverse transformation.

This article has been cited by other articles:

				M. Wirtenberger, J. Schmutzhard, K. Hemminki, A. Meindl, C. Sutter, R. K. Schmutzler, B. Wappenschmidt, M. Kiechle, N. Arnold, B. H.F. Weber, et al. The functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer Carcinogenesis, February 1, 2007; 28(2): 423 - 426. [Abstract] [Full Text] [PDF]

				A. Porcellini, S. Messina, G. De Gregorio, A. Feliciello, A. Carlucci, M. Barone, A. Picascia, A. De Blasi, and E. V. Avvedimento The Expression of the Thyroid-stimulating Hormone (TSH) Receptor and the cAMP-dependent Protein Kinase RII {beta} Regulatory Subunit Confers TSH-cAMP-dependent Growth to Mouse Fibroblasts J. Biol. Chem., October 17, 2003; 278(42): 40621 - 40630. [Abstract] [Full Text] [PDF]

				C. Rohlff, S. Ahmad, F. Borellini, J. Lei, and R. I. Glazer Modulation of Transcription Factor Sp1 by cAMP-dependent Protein Kinase J. Biol. Chem., August 22, 1997; 272(34): 21137 - 21141. [Abstract] [Full Text] [PDF]

				M. J. Miller, A. Martinez, E. J. Unsworth, C. J. Thiele, T. W. Moody, T. Elsasser, and F. Cuttitta Adrenomedullin Expression in Human Tumor Cell Lines. ITS POTENTIAL ROLE AS AN AUTOCRINE GROWTH FACTOR J. Biol. Chem., September 20, 1996; 271(38): 23345 - 23351. [Abstract] [Full Text] [PDF]